42918-86-5

Basic information

• Product Name: Z-ABU-OH
• Synonyms: (S)-Cbz-2-aMinobutyric acid;Z-D-Abu;Z-L-α-aminobutyric acid;Cbz-2-Abu-OH;Z-L-Abu-OH;Z-L-α-aminobutyric acid≥ 98% (HPLC);BENZYLOXYCARBONYL-L-2-AMINOBUTYRIC ACID;Z-2-ABU-OH
• CAS NO: 42918-86-5
• Molecular Formula: C₁₂H₁₅NO₄
• Molecular Weight: 237.25
• EINECS: 1533716-785-6
• Mol File: 42918-86-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 430.3 °C at 760 mmHg
• Flash Point: 214 °C
• Appearance: /
• Density: 1.213 g/cm³
• Vapor Pressure: 3.61E-08mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: Store at RT.
• CAS DataBase Reference: Z-ABU-OH(CAS DataBase Reference)
• NIST Chemistry Reference: Z-ABU-OH(42918-86-5)
• EPA Substance Registry System: Z-ABU-OH(42918-86-5)

Safety Data

• Hazardous Substances Data: 42918-86-5(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Uses

(S)-Cbz-2-aminobutyric Acid can be used as inhibitors in treatment of gastrointestinal and mental disorders.

InChI:InChI=1/C12H15NO4/c1-2-10(11(14)15)13-12(16)17-8-9-6-4-3-5-7-9/h3-7,10H,2,8H2,1H3,(H,13,16)(H,14,15)/t10-/m0/s1

Upstream product

• 1492-24-6 L-2-aminobutyric acid 
• 501-53-1 benzyl chloroformate 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 
• 917-54-4 methyllithium 
• 56-84-8 L-Aspartic acid 
• 31139-36-3 dibenzyl dicarbonate 
• 127862-66-2 2-Benzyloxycarbonylamino-butyric acid 2,2,2-trifluoro-ethyl ester 
• 20395-87-3 2-(N-benzyloxycarbonylamino)butyric acid 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 

Downstream Products

• 1170-50-9 Benzyloxycarbonyl-α-amino-butyrylglutamin 
• 116823-65-5 Z-Abu-Sar-(Me)Leu-Val-(Me)Leu-Ala-D-Ala-(Me)Leu-(Me)Leu-(Me)Val-OBut 
• 22373-14-4 [(1S)-1-(hydroxymethyl)propyl]carbamic acid benzyl ester 
• 71447-81-9 N-benzyloxycarbonyl-(2S)-aminobutyric acid succinimide ester 
• 922705-22-4 phenylmethyl [(1S)-3-diazo-1-ethyl-2-oxopropyl]carbamate 
• 95656-94-3 phenylmethyl (4S)-5-oxo-4-ethyl-1,3-oxazolidine-3-carboxylate 
• 17327-61-6 N-Benzyloxycarbonyl-L-α-aminobuttersaeure-Phe-amid 
• 305859-68-1 (R,S)-4-benzyloxycarbonylamino-4,5-dihydro-2(3H)-furanone 
• 1398817-33-8 C₃₄H₅₅NO₆ 
• 1619922-67-6 Z-Abu-NH^tBu 
• 92235-10-4 N-((S)-2-benzyloxycarbonylamino-butyryl)-glycine ethyl ester 
• 132562-61-9 N-((S)-2-amino-butyryl)-L-tyrosine ethyl ester; hydrochloride 

Relevant articles and documents

Identification, characterization, synthesis and strategy for minimization of potential impurities observed in the synthesis of brivaracetam

A first systematic impurity profile research concerning nine observed and potential process related impurities of antiepileptic drug brivaracetam is reported. Among which three (impurity G/H/I) have not been discovered or reported before, these nine impurities were monitored by HPLC, and their structures were identified on the basis of MS and NMR spectroscopy. In addition to the formation, synthesis, and characterization, strategies for minimizing these impurities to the levels accepted by ICH are also described in this report.

Assay and inhibition of diacylglycerol lipase activity

A series of N-formyl-α-amino acid esters of β-lactone derivatives structurally related to tetrahydrolipstatin (THL) and O-3841 were synthesized that inhibit human and murine diacylglycerol lipase (DAGL) activities. New ether lipid reporter compounds were developed for an in vitro assay to efficiently screen inhibitors of 1,2-diacyl-sn-glycerol hydrolysis and related lipase activities using fluorescence resonance energy transfer (FRET). A standardized thin layer chromatography (TLC) radioassay of diacylglycerol lipase activity utilizing the labeled endogenous substrate [1″- 14C]1-stearoyl-2-arachidonoyl-sn-glycerol with phosphorimaging detection was used to quantify inhibition by following formation of the initial product [1″-14C]2-arachidonoylglycerol and further hydrolysis under the assay conditions to [1-14C]arachidonic acid.

THIAZOLIDINE DERIVATIVES

An object of the present invention is to provide novel thiazolidine derivatives which are useful as drugs. The thiazolidine derivatives according to the present invention are compounds represented by the following general formula [I] and salts thereof, wherein R 1is alkyl, hydroxy, alkoxy, alkoxyalkyl, phenyl, phenylalkyl, phenylalkoxy, phenoxy, phenoxyalkyl, amino, alkylamino or a nonaromatic heterocycle; R 2is H or alkyl; R 3is H, alkyl or phenyl; R 4is H or alkyl; R 5is alkyl, halogenoalkyl, hydroxy, alkoxy, phenyl, phenylalkoxy, phenoxy, carboxyl, alkoxycarbonyl, phenylalkoxycarbonyl or an aromatic heterocycle; A 1is alkylene; and A 2is alkylene.